Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 131–140, page 14 of 20. Filter these by subject, year and score in the research library →

1. Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting systemResearch summary

   Research summaries · alzhub.org/study/comparison-of-safety-of-lecanemab-and-donanemab-a-real-world-42440686

   … including 2,602 for lecanemab and 1,038 for donanemab. Conclusion Using four signal detection algorithms, this study compared real-world adverse event reporting profiles associated with lecanemab and donanemab. These findings …

2. Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality StatusResearch summary

   Research summaries · alzhub.org/study/demographic-and-clinical-characteristics-of-patients-treated-with-42732414

   … considerations during lecanemab treatment for Alzheimer's disease (AD). Although APOE ε4 carrier status is a recognized ARIA risk factor, the relationship between ARIAs and routine demographic and clinical characteristics in …

3. Effect of Lecanemab in Early Alzheimer's Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 PerspectiveResearch summary

   Research summaries · alzhub.org/study/effect-of-lecanemab-in-early-alzheimer-s-disease-mechanistic-37212119

   In clinical trials, lecanemab and donanemab showed statistically significant yet marginal slowdown of Alzheimer's disease (AD)-associated cognitive decline. This could be due to their sub-optimal design and/or deployment; …

4. Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/interim-analysis-of-all-case-post-marketing-surveillance-study-in-41849958

   Background Lecanemab is a monoclonal antibody targeting amyloid-beta protofibrils, indicated for patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease. Objectives This study reports interim …

5. Lecanemab in symptomatic PSEN1 p.Met233Val early-onset Alzheimer's disease: Neuroimaging safety, regional amyloid-PET dynamics, and longitudinal plasma biomarkersResearch summary

   Research summaries · alzhub.org/study/lecanemab-in-symptomatic-psen1-p-met233val-early-onset-alzheimer-s-42676462

   … (ADAD) variant for which lecanemab response data are unavailable. Methods A 34-year-old symptomatic PSEN1 p .Met233Val carrier (APOE ε3/ε3) was prospectively followed through 26 lecanemab infusions over 12 months, with serial …

6. Leqembi Recommended for Treatment of Early Alzheimer's Disease (CHMP re-examination, reversing July 2024 refusal)Research summary

   Research summaries · alzhub.org/study/leqembi-recommended-for-treatment-of-early-alzheimer-s-disease-chmp-6280b4fa

   … initially refused to approve lecanemab in the EU in July 2024, judging that its modest effect on cognitive decline did not outweigh ARIA risk in the broad early-Alzheimer's population studied. After Eisai requested a …

7. Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation ModelingResearch summary

   Research summaries · alzhub.org/study/long-term-health-outcomes-of-lecanemab-in-patients-with-early-35469060

   … common cause of dementia. Lecanemab is a humanized monoclonal antibody targeting amyloid protofibrils for the treatment of early AD. In the phase II BAN2401-G000-201 trial (NCT01767311), lecanemab reduced amyloid accumulated in …

8. Real world clinical practice of lecanemab at PUMCH dementia cohort: focus on dynamic imaging and biomarker evolutionResearch summary

   Research summaries · alzhub.org/study/real-world-clinical-practice-of-lecanemab-at-pumch-dementia-cohort-41520099

   … this real-world cohort, lecanemab reduced amyloid on PET scans, and although cognitive and functional scores still worsened, the rate of progression was slower than in a control group. Brain imaging also showed volume reduction …

9. Real-world implementation of lecanemab in Korean patients at a tertiary memory clinic: Safety, ARIA risk, and early treatment patternsResearch summary

   Research summaries · alzhub.org/study/real-world-implementation-of-lecanemab-in-korean-patients-at-a-42591325

   Introduction Lecanemab has demonstrated clinical efficacy in early Alzheimer's disease (AD), but real-world data remain limited, particularly in Asian populations. Methods We prospectively enrolled 127 patients across the AD …

10. Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181Research summary

    Research summaries · alzhub.org/study/real-world-long-term-continuation-of-lecanemab-therapy-and-the-42664573

    … long-term feasibility of lecanemab treatment in 117 patients with early Alzheimer's disease at Kanazawa University Hospital. To assess treatment persistence over a full 18-month course, we focused on the 64 patients who initiated …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.